Business Description
![Qualigen Therapeutics Inc Qualigen Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000BUM1.png?14)
Qualigen Therapeutics Inc
NAICS : 541713
SIC : 8731
ISIN : US74754R2022
Share Class Description:
FRA:7R9: Ordinary SharesDescription
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | -1.04 | |||||
Debt-to-Equity | -0.62 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -99.89 | |||||
Beneish M-Score | -11.7 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -28.2 | |||||
3-Year EPS without NRI Growth Rate | -20.9 | |||||
3-Year FCF Growth Rate | -165.1 | |||||
3-Year Book Growth Rate | 38.2 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.47 | |||||
9-Day RSI | 27.74 | |||||
14-Day RSI | 30.6 | |||||
6-1 Month Momentum % | -59.06 | |||||
12-1 Month Momentum % | -77.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.28 | |||||
Quick Ratio | 0.28 | |||||
Cash Ratio | 0.1 | |||||
Days Inventory | 244.4 | |||||
Days Sales Outstanding | 62.98 | |||||
Days Payable | 226.2 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -62.3 | |||||
Shareholder Yield % | -5.7 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 29.44 | |||||
Operating Margin % | -380.21 | |||||
Net Margin % | -414.87 | |||||
FCF Margin % | -323.74 | |||||
ROE % | -645.42 | |||||
ROA % | -123.1 | |||||
ROIC % | -125.49 | |||||
ROC (Joel Greenblatt) % | -841.44 | |||||
ROCE % | -314.34 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.31 | |||||
EV-to-EBIT | -0.18 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-Revenue | 0.67 | |||||
EV-to-Forward-Revenue | 0.01 | |||||
EV-to-FCF | -0.2 | |||||
Earnings Yield (Greenblatt) % | -555.56 | |||||
FCF Yield % | -840.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qualigen Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 3.003 | ||
EPS (TTM) (€) | -2.472 | ||
Beta | -0.48 | ||
Volatility % | 51.26 | ||
14-Day RSI | 30.6 | ||
14-Day ATR (€) | 0.013406 | ||
20-Day SMA (€) | 0.20095 | ||
12-1 Month Momentum % | -77.89 | ||
52-Week Range (€) | 0.139 - 1.096 | ||
Shares Outstanding (Mil) | 6.31 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Qualigen Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Qualigen Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Qualigen Therapeutics Inc Frequently Asked Questions
What is Qualigen Therapeutics Inc(FRA:7R9)'s stock price today?
The current price of FRA:7R9 is €0.14. The 52 week high of FRA:7R9 is €1.10 and 52 week low is €0.14.
When is next earnings date of Qualigen Therapeutics Inc(FRA:7R9)?
The next earnings date of Qualigen Therapeutics Inc(FRA:7R9) is .
Does Qualigen Therapeutics Inc(FRA:7R9) pay dividends? If so, how much?
Qualigen Therapeutics Inc(FRA:7R9) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |